GAMMA Investing LLC Increases Stock Holdings in Smith & Nephew plc (NYSE:SNN)

GAMMA Investing LLC increased its position in shares of Smith & Nephew plc (NYSE:SNN - Free Report) by 3,372.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 103,295 shares of the medical equipment provider's stock after acquiring an additional 100,320 shares during the period. GAMMA Investing LLC's holdings in Smith & Nephew were worth $2,930,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Principal Securities Inc. lifted its stake in Smith & Nephew by 87.6% during the 4th quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock worth $36,000 after acquiring an additional 691 shares in the last quarter. National Bank of Canada FI lifted its stake in Smith & Nephew by 36.5% during the 4th quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock worth $41,000 after acquiring an additional 446 shares in the last quarter. Hara Capital LLC lifted its stake in Smith & Nephew by 391.4% during the 4th quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock worth $60,000 after acquiring an additional 1,957 shares in the last quarter. Versant Capital Management Inc lifted its stake in Smith & Nephew by 1,970.2% during the 1st quarter. Versant Capital Management Inc now owns 5,217 shares of the medical equipment provider's stock worth $148,000 after acquiring an additional 4,965 shares in the last quarter. Finally, Quadrant Capital Group LLC increased its holdings in Smith & Nephew by 37.4% during the 4th quarter. Quadrant Capital Group LLC now owns 7,431 shares of the medical equipment provider's stock worth $183,000 after purchasing an additional 2,024 shares during the period. Institutional investors and hedge funds own 25.64% of the company's stock.

Analyst Ratings Changes

SNN has been the topic of several recent research reports. Canaccord Genuity Group upped their price target on Smith & Nephew from $27.00 to $28.00 and gave the stock a "hold" rating in a report on Thursday, May 1st. UBS Group downgraded Smith & Nephew from a "buy" rating to a "neutral" rating in a report on Wednesday, March 12th. Hsbc Global Res downgraded Smith & Nephew from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. HSBC downgraded Smith & Nephew from a "buy" rating to a "hold" rating in a report on Friday, April 25th. Finally, Wall Street Zen upgraded Smith & Nephew from a "buy" rating to a "strong-buy" rating in a report on Wednesday, February 26th. Six equities research analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $28.00.

Smith & Nephew Stock Performance

NYSE:SNN traded down $0.12 during mid-day trading on Monday, reaching $29.27. 816,430 shares of the stock were exchanged, compared to its average volume of 800,235. The company has a 50 day simple moving average of $28.04 and a 200-day simple moving average of $26.88. The stock has a market capitalization of $12.82 billion, a P/E ratio of 13.55, a P/E/G ratio of 1.26 and a beta of 0.68. The company has a quick ratio of 1.11, a current ratio of 2.51 and a debt-to-equity ratio of 0.63. Smith & Nephew plc has a 1 year low of $23.69 and a 1 year high of $31.72.

Smith & Nephew Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.